Simplify Logo

Full-Time

Scientist – Disease Area Biology

Posted on 8/16/2024

Korro Bio

Korro Bio

51-200 employees

Develops RNA-based therapies for diseases

Biotechnology
Healthcare

Mid, Senior

Cambridge, MA, USA

Onsite position at 60 first st, cambridge, ma 02141.

Category
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • MS (3+ years’ experience) /BS (5+years’ experience) in molecular and/or cellular biology, or a related field
Responsibilities
  • Responsible for the design, execution and analysis of a variety of in vitro cellular and molecular biology assays, focused on understanding and optimizing our ADAR-mediated RNA editing platform
  • Evaluate and troubleshoot new assays and techniques, as well as balancing a variety of tasks
  • Participate in the development and scaling of novel cell-based assays
  • Deployment of cell-based models and assays for drug candidate screening and mechanism of action understanding
  • Design, validate and implement high throughput NGS, dPCR and qPCR-based assays
  • Design and implement thoughtful and well-controlled experiments
  • Work with various types of automated high throughput equipment

Korro Bio develops RNA-based therapies aimed at treating serious diseases that lack effective treatments. The company uses RNA editing to make precise modifications at the RNA level, which allows for accurate changes in protein function. This method is seen as more precise and potentially safer than traditional gene editing techniques. Korro Bio focuses on research and development to create new therapies, which it can market independently or through partnerships with larger pharmaceutical companies. The company serves healthcare providers, hospitals, and patients, and collaborates with academic institutions to enhance its research. Korro Bio's goal is to advance RNA editing technology to provide new treatment options for patients suffering from debilitating diseases.

Company Stage

IPO

Total Funding

$451.5M

Headquarters

Cambridge, Massachusetts

Founded

2019

Growth & Insights
Headcount

6 month growth

3%

1 year growth

1%

2 year growth

30%
Simplify Jobs

Simplify's Take

What believers are saying

  • The $70 million raised for clinical trials and growth positions Korro Bio to advance its pipeline and achieve significant milestones.
  • The appointment of industry veterans like Dr. Rachel Meyers and Tim Pearson to the board strengthens the company's leadership and strategic direction.
  • Korro Bio's stock price surge of 171% in November indicates strong market confidence and potential for high returns.

What critics are saying

  • The biopharmaceutical market is highly competitive, and Korro Bio must continuously innovate to maintain its edge.
  • The success of RNA editing therapies is still uncertain and hinges on successful clinical trials and regulatory approvals.

What makes Korro Bio unique

  • Korro Bio's focus on RNA editing allows for precise single base modifications, offering a potentially safer and more accurate alternative to traditional gene editing and gene therapy.
  • The company's strategy of leveraging machine learning to enhance RNA delivery and platform development sets it apart from competitors.
  • Korro Bio's recent $70 million private placement and merger with Frequency Therapeutics provide substantial financial backing and expanded capabilities.
INACTIVE